Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Investigators from the National Health and Nutrition Examination Survey estimate that 136.8 million adults met the criteria for at least one of three approved indications for semaglutide diabetes, weight management, or secondary cardiovascular disease prevention:
It is administered once weekly by subcutaneous injection, with doses escalated gradually from a low starting dose up to 12 mg weekly in Phase 2 trials
Mol Metab 30:72130 Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D (2021) The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Phase 3 outcomes will be critical to confirm sustained efficacy, cardiovascular benefit, tolerability at scale, and real-world adherence
1 2 "Trulicity EPAR"
US$ 28.68
US$ 22.69
US$ 26.47
US$ 21.01
US$ 20.03
US$ 29.67
US$ 24.51
